



Palatin Technologies, Inc.  
NYSE American: PTN

CORPORATE PRESENTATION  
February 2026

Carl Spana, Ph.D.  
President & CEO

Stephen T. Wills, CPA/MST  
CFO / COO



# Forward Looking Statements

---

The statements in this presentation that relate to future plans, events or performance are forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended. Such forward-looking statements involve significant risks and uncertainties, and actual results, events and performance may differ materially from those expressed or implied in this presentation. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements concerning the following: (i) estimates of our expenses, future revenue and capital requirements; (ii) our ability to obtain additional funding on terms acceptable to us, or at all; (iii) our ability to advance product candidates into, and successfully complete, clinical trials; (iv) the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs; (v) the timing or likelihood of regulatory filings and approvals; (vi) our expectation regarding timelines for development of our other product candidates; (vii) the potential for commercialization of our other product candidates, if approved for commercial use; (viii) our ability and the ability of our licensees to compete with other products and technologies similar to our product candidates; (ix) the ability of third party collaborators to timely carry out their duties under their agreements with us and our licensees; (x) the ability of contract manufacturers to perform their manufacturing activities in compliance with applicable regulations; (xi) our ability to recognize the potential value of our licensing arrangements with third parties; (xii) the potential to achieve revenues from the sale of our product candidates; (xiii) our ability to maintain product liability insurance at a reasonable cost or in sufficient amounts, if at all; (xiv) the retention of key management, employees and third-party contractors; (xv) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (xvi) our compliance with federal and state laws and regulations; (xvii) the timing and costs associated with obtaining regulatory approval for our product candidates; (xviii) the impact of legislative or regulatory healthcare reforms in the United States; and (xix) other risks disclosed in our SEC filings. The forward-looking statements in this presentation do not constitute guarantees of future performance. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date of this presentation.

# Company Profile

*Technology platform – targeting the melanocortin system*

## Therapeutics for Obesity, Inflammatory & Autoimmune Diseases



Demonstrated expertise moving programs from discovery to FDA approval



Expertise in the biology and chemistry of melanocortin system (MCS)



1<sup>st</sup> company to gain FDA approval for a melanocortin agent - Vyleesi<sup>®</sup> for female sexual dysfunction



MOA with potential to modify underlying disease pathologies – not just treat symptoms



Strategy leverages our expertise across multiple therapeutic opportunities

# Palatin Leadership

*Strong team, with broad and extensive biopharma experience*



**Carl Spana, PhD**  
*President and Chief Executive Officer*

Co-founder with 25-plus years in drug research, development, approval and board directorships



**Stephen T. Wills, CPA/MST**  
*Chief Financial Officer and Chief Operating Officer*

25-plus years in finance, operations, M&A, licensing, capital markets and board directorships

**John Dodd, PhD**  
*Senior Vice President Research / Development*

40-plus years in drug discovery and development

**J. Don Wang, PhD**  
*Vice President Product Development*

30-plus years in CMC and supply chain

**Stephen A. Slusher**  
*Chief Legal Officer*

30-plus years of legal leadership with a focus on Intellectual property

**Robert Jordan**  
*Senior Vice President Program Operations*

20-plus years in drug development and clinical operations

**James Hattersley**  
*Senior Vice President Business Development*

25-plus years of identifying and executing deals



**Johnson & Johnson**  
**Caltech**



# Development Programs

*Novel 'next generation' MC4R agonists for treatment of acquired and congenital obesity*

## Multiple Clinical Trials Targeted in 2026 with Novel MC4R Compounds


Product/Indication	R&D	Phase 1	Phase 2	Phase 3	NDA	Status/Next Steps
<b>PL7737 Oral Small Molecule MC4R Agonist</b> Multiple obesity indications with focus on hypothalamic obesity						Daily dosing format <b>IND enabling – CMC activities ongoing</b> <b>IND filing 1H26</b> <b>Phase 1 SAD/MAD start 1H26 / data 2H26</b>
<b>Novel Once-Weekly Peptide MC4R Agonist</b> Multiple obesity indications with focus on hypothalamic obesity						Identify optimal compound 1H26 Daily and extended dosing formats <b>IND enabling – CMC activities ongoing</b> <b>IND filing mid-2026</b> <b>Phase 1 SAD/MAD start 2H26 / data 2H26</b>
<b>Bremelanotide (PoC Study)</b> Obesity GLP-1 adjunct therapy Proof-of-concept study only						Phase 2 - tirzepatide patients <b>Positive Topline data reported 1Q25</b>

Hypothalamic Obesity (HO) patients to be included in Phase 1 SAD/MAD studies / program

PL7737 granted FDA orphan drug designation for obesity due to leptin receptor (LEPR) deficiency

# MC4R Obesity Programs

*MC4R pathway regulates obesity and energy management through satiety & food intake*



Central leptin-melanocortin pathway is a critical pathway that regulates feeding and body weight to maintain energy homeostasis

# Hypothalamic Obesity (HO)

---

# Hypothalamic Obesity (HO)


*A rare, form of obesity following injury to the hypothalamus*

## Acquired HO

- **Craniopharyngioma** are brain tumors that develop near the hypothalamus and pituitary gland
- Treatments include tumor resection surgery, radiation or both
- Treatment damages the hypothalamus leading to disruption of **MC4R signaling pathway** causing reduced energy, hyperphagia and rapid-onset, severe obesity

## Congenital HO

- Hypothalamic dysfunction as a result of a genetic disorder which can disrupt **MC4R signaling pathway** causing reduced energy, hyperphagia and rapid-onset, severe obesity



[together.stjudes.org](http://together.stjudes.org)

# MC4R Obesity Programs for Treating Acquired and Congenital Obesity

*Palatin's next generation melanocortin agonists for the advanced treatment of HO*

## Acquired Hypothalamic Obesity (HO)

5,000 – 10,000  
estimated U.S. prevalence\*



3,500 – 10,000  
estimated European prevalence\*\*



5,000 – 8,000  
estimated Japanese prevalence\*\*\*



- ✓ High unmet and unsatisfied medical need
- ✓ MC4R agonism is a validated target
- ✓ Patients will require life-long treatment
- ✓ Patients are easily identified
- ✓ Patients are engaged with the health system receiving specialist care for endocrine complications

\* U.S. estimates based on reported incidence of hypothalamic obesity following craniopharyngioma and long-term survival rates, (Zacharia, et al., Neuro-Oncology 14(8):1070–1078, 2012. doi:10.1093/neuonc/nos142; and Muller, et al., Neuro-Oncology 17(7), 1029–1038, 2015 doi:10.1093/neuonc/nov044.)

\*\* European estimates limited to the EU4 (Germany, France, Spain, Italy), UK and the Netherlands and prevalence of 0.1-0.3 in 10,000 patients

\*\*\* Palatin estimates the prevalence of acquired hypothalamic obesity in Japan to be approximately 5,000 to 8,000 based on our review of certain data; Prevalence is 2-3 times higher than in the USA & Europe due to a higher reported frequency of craniopharyngioma.

## Melanocortin-4 Receptor (MC4R) Obesity Programs

- *Novel “Next Generation” MC4R Selective Agonists*
  - *PL7737 Oral MC4R Selective Small Molecule*
  - *MC4R Selective Peptides Once Weekly Dosing*

# Melanocortin-4 Receptor (MC4R) Obesity Programs

*MC4R selective oral small molecule programs for acquired and congenital obesity*

## Current Therapy Challenges

Injection Frequency

Skin Pigmentation

Nausea / Vomiting

Cardiovascular Effects

## Palatin Achieved Solutions



Palatin identified small molecules show excellent preclinical oral bioavailability



Palatin small molecules interact weakly with MC1 receptors, and with limited potential to cause skin pigmentation



Palatin research has identified multiple approaches to reduce GI AE's



Multiple structural features in Palatin compounds have demonstrated the ability to eliminate cardiovascular effects


# MC4R Obesity Programs for Acquired and Congenital Obesity

*Novel “next generation” MC4R selective agonists: understanding what is required for success*

***Historically, MC4R small molecule programs have failed due to a lack of understanding the receptor biology and the structure/function relationship that determine weight loss versus side effects.***

Target profile for orally active selective MC4R agonist:



- Optimal PK curve for max therapeutic window
- Properties required for a successful oral small molecule
  - ✓ Molecular weight
  - ✓ Polar surface area
  - ✓ hERG activity
  - ✓ Human plasma protein binding
  - ✓ CYP activity
- MC4R mechanism-based weight loss
- Limited MC1R activity (hyperpigmentation minimized)
- No sexual or blood pressure effects
- 30-day non-GLP toxicity completed
- IP protection out to 2044, with patent term extension



**Palatin's PL7737 has the TARGET PROFILE for a successful MC4R selective, oral small molecule entity.**

# MC4R Obesity Programs for Acquired and Congenital Obesity

*Ideal PK profile for an obesity treatment (PK consistency across mouse, rat, dog)*






- Oral administration
- Protein binding facilitates efficacious levels without surpassing them
- PL7737 does not have a high transient Cmax helps to avoid AE's
- Once per day dosing with steady state reached day 3
- Low PK variability

# MC4R Obesity Programs for Acquired and Congenital Obesity

*MC4R selective oral small molecule PL7737 @ 3, 10 and 30mg/kg reduces body weight in DIO mice*

***PL7737 is a novel MC4R selective oral small molecule agonist.***





- PL7737 oral dosing days 0, 1 & 2
- PL8905 SC BID (selective peptide MC4R agonist)
- Oral treatment with PL7737 resulted in significant body weight loss
- Effects of PL7737 is MC4R dependent

# MC4R Obesity Programs for Acquired and Congenital Obesity

*Oral PL7737 monotherapy causes significant weight loss in diet-induced obesity (DIO) rats*

**PL7737 is a novel MC4R selective oral small molecule agonist.**



- PL7737 dosed orally at 3, 10 and 30mg/kg
- PL7737 monotherapy had rapid, dose-dependent weight loss with of 4 days of tx
- PL7737 + Tirzepatide - additive effect on weight loss
- No observed hyperpigmentation

[NOTE: Dose of tirzepatide = 2 nmol/kg, SC injection, once daily]

# MC4R Obesity Programs for Acquired and Congenital Obesity

*Current & planned activities for PL7737 novel MC4R selective oral small molecule agonist*

## IND-enabling toxicology activities started

- Toxicology studies ongoing
- IND planned for submission in 1H 2026

## CMC activities ongoing

- Target dose 160mg QD
- Non-GMP tox API being manufactured
- GMP clinical API manufacture initiated
- Phase 1/2 drug product planned for delivery by year end 2025

## Phase 1 SAD/MAD, including hypothalamic obesity (HO) patients, planned for 1H 2026 start

- SAD data 2H 2026
  - Healthy obese patients
- MAD data 2H 2026
  - Healthy obese patients and a cohort of HO patients

# Novel "Next Generation" MC4R Selective Peptide Agonists

*Legacy challenges of MC4R peptide agonists have been solved*

## Current Therapy Challenges

Injection Frequency

Skin Pigmentation

Nausea / Vomiting

Cardiovascular Effects

## Palatin Achieved Solutions



Palatin's compounds with high potency coupled with structural elements, extend drug residency time ( $\geq 1$  week)



Multiple structural elements have been identified by Palatin and demonstrate reduced MC1R agonism (a known contributor to hyperpigmentation)



Palatin research has identified multiple approaches to reduce gastrointestinal AE's



Palatin structure-function studies have identified achievable modifications which eliminate cardiovascular effects

# Novel "Next Generation" MC4R Selective Peptide Agonists

---

## First series of 'next generation' MC4R peptide agonists for obesity:

- Palatin studies in MC4R knock-out model confirm weight loss is dependent on a functional MC4R
- PL8905 potential lead development candidate
  - Selective MC4R agonist: Significant multiples of binding selectivity for MC4R over MC1R
  - Protein binding tail added for extended duration
  - Efficacy in weight loss and food intake at without blood pressure effects
  - Confirms validity of structure/function relationships
    - ✓ New compounds extend the selectivity for MC4R over MC1R

## Second series of 'next generation' MC4R peptide agonists for obesity:

- Palatin has generated novel structures/compounds that bias for MC4R selectivity over MC1R
  - Extended *in vivo* stability allows for 1x weekly dosing
  - Hyperpigmentation minimized

# Novel "Next Generation" MC4R Selective Peptide Agonists

*Second series - new Palatin peptide compounds reduce/eliminate MC1R agonism*

Agonist	MC1R EC <sub>50</sub> (E <sub>max</sub> )	MC4R EC <sub>50</sub> (E <sub>max</sub> )	MC4R Selectivity <sup>a</sup>
<b>Bremelanotide</b>	0.23 nM (91.8%)	5.01 nM (91.0%)	0.05
<b>Setmelanotide</b>	0.4 nM (106%)	0.66 nM (98.8%)	0.61
<b>PL8905</b>	30.2 nM (78.5%)	4.99 nM (88.3%)	6.05
<b>2</b>	199.6 nM (98.8%)	2.99 nM (107.4%)	66.76
<b>3</b>	69.1 nM (89.9%)	0.74 nM (94.9%)	93.38
<b>4</b>	352.3 nM (32.5%)	9.69 nM (90.5%)	Undefined <sup>b</sup>

- MC1R agonism results in skin darkening
- Bremelanotide is FDA approved for treating hypoactive sexual desire disorder in women
- Setmelanotide is FDA approved for treating several orphan obesity indications


<sup>a</sup>Selectivity is defined as ratio of MC4R EC<sub>50</sub> to MC1R EC<sub>50</sub> (larger # is more MC4R relative to MC1R)

<sup>b</sup>Undefined indicates that the compound is not an agonist at MC1R


# Novel "Next Generation" MC4R Selective Peptide Agonists

*In vivo PL8905 weight loss studies in diet-induced obese (DIO) and MC4R knockout (KO) mice*

Change in Body Weight






Body Weight in Wild Type DIO Mice and MC4R-Knockout Mice



# Novel "Next Generation" MC4R Selective Peptide Agonists

## *Proprietary technology for extending peptide PK*



- Proprietary technology for extending peptide pk
- Allows for additional patent protection
- Allows for once weekly dosing

# Novel "Next Generation" MC4R Selective Peptide Agonists

## *Current/Planned activities – long-acting once weekly administration SC peptides*

Highly selective MC4R agonists to avoid hyperpigmentation, no blood pressure effects and enabling once weekly injection into one compound accomplished

- Multiple candidates being profiled for receptor selectivity, PK analysis and efficacy in obesity models
- Novel intellectual property with full term patent coverage
- Final development candidate will be selected based on superior profile
  - High selectivity for MC4R over MC1R
    - Potential to eliminate hyperpigmentation
  - PK that supports  $\geq 1$  week dosing
  - Excellent weight loss in obesity models
- IND enabling studies planned for 1H 2026
- IND submission planned for mid-2026
- Phase 1 SAD/MAD 2H 2026

# Melanocortin-4 Receptor (MC4R) Obesity Programs

## *Obesity program next steps*

***Treating general obesity & rare obesity indications: primary focus on hypothalamic obesity (HO).***

### Development Timeline

- MC4R agonists:
  - PL7737 oral (daily) small molecule
  - Long-acting peptide (weekly SC administration)
- **IND submissions planned 1H26 and mid-2026**
- Phase 1 SAD/MAD clinical study initiation expected 1H 2026 / **Topline data target 2H 2026**
  - Hypothalamic obesity patients will be included in Phase 1 program
- Phase 2 clinical study initiation (HO patients only) targeted for 1H 2027

### Strategic Opportunity in Hypothalamic Obesity


- Clinically validated mechanism for safe, effective treatment of obesity
- Significant unmet need
- MC4R is a validated target
- Potential best-in-class MC4R oral and long-acting peptide therapies

## MC4R Agonist Generalized Obesity Management

- *Bremelanotide MC4R agonist Phase 1b clinical weight loss study in general obese subjects*
- *Co-administration of Bremelanotide MC4R & Tirzepatide (GLP-1/GIP)*
  - *Bremelanotide (BMT) MC4R Agonist*
    - ✓ *FDA Approved (Vyleesi® for Female HSDD)*

# MC4R Agonist Generalized Obesity Management

*Bremelanotide MC4R agonist obesity Phase 1b clinical weight loss study in general obese subjects*



## 2-Week Study

- General obese subjects: BMI ~35
  - Bremelanotide: n=27
  - Vehicle: n=26
- Weight loss:
  - Placebo -0.7kg;
  - Bremelanotide: -2.2kg p<0.001
- Bremelanotide reduction daily caloric intake ~400kcal p<0.01
- Steady weight loss over the duration of treatment

# MC4R Agonist Generalized Obesity Management

## GLP-1/GIP agonist + MC4R agonist: co-administration clinical data\*

- No prospective studies have been done with combination pharmacotherapy
- Previously published combination of setmelanotide plus 2.5mg of tirzepatide for obesity in BBS
- 2 patients lost 26% in 34 weeks and 30% TBW at 52 weeks never moving past 2.5mg dose

Patient 1 change in BMI




Image 1: Rate of change of BMI in Patient 1 taking combination therapy over a 52-week period.

Patient 2 change in BMI




Image 2: Rate of change of BMI in Patient 2 taking combination therapy over a 34-week period.

# MC4R Agonist Generalized Obesity Management

## *BMT-801 Phase 2 signal detection study objectives*

### **Co-Administration GLP1/GIP Agonist Tirzepatide (2.5mg Weekly) + MC4R Agonist Bremelanotide (1.25mg Daily)**

#### Main Research Questions

- Does co-administration result in increased weight loss?
- Does MC4R agonism blunt the weight regain seen post-incretin treatment?
- Evaluate the safety and tolerability of co-administration

#### Pro's

- Appropriate control arms included
- Co-administration arm powered to see a statistically significant weight loss effect
- Evaluating a comprehensive set of secondary end points

#### Limitations

- MC4R agonist given at a low dose 1x day in the morning
- Not powered for between arm comparisons
- Short duration of treatment


Combination therapy will be an important approach in helping many subjects reach their weight loss goals

# MC4R Agonist Generalized Obesity Management

## BMT-801 Phase 2 signal detection study

### Co-Administration GLP1/GIP Agonist Tirzepatide & MC4R Agonist Bremelanotide

**Study Design:** Randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of the addition of an MC4R agonist (BMT) to tirzepatide in n=96 obese subjects



**Primary endpoint:** % change in weight loss tirzepatide/bremelanotide compared to pbo/pbo at week 8

**Additive effect of BMT:**


- % of subjects with  $\geq 5\%$  weight loss at week 8 tirzepatide/bremelanotide compared to tirzepatide/pbo
- % subjects greater weight loss in Treatment Period 2 vs Treatment Period 1, tirzepatide/bremelanotide compared to tirzepatide/pbo
- % change in weight loss tirzepatide/bremelanotide compared to tirzepatide/pbo Treatment Period 2 (week 4-week 8)

**Weight loss maintenance:** % change weight loss bremelanotide/pbo vs pbo/pbo (week 4-week 8)

# MC4R Agonist Generalized Obesity Management


## *Co-administration additive effect – primary analysis*

### Analysis for Additive Effect Percent of Subjects with $\geq 4\%$ Reduction in Percent Weight Loss at End of Study



# MC4R Agonist Generalized Obesity Management

## *Effect of co-administration on increased weight loss*




- Comparison of Group 4 to Group 3 during Treatment Period 2 demonstrates a **weight loss maintenance effect**
- Comparison Group 1 to Group 2 at week-8 demonstrates **additive effect of co-administration**
- Rapid weight regain seen post-treatment**

# MC4R Agonist Generalized Obesity Management

## *BMT-801 MC4R/GLP-1-GIP co-administration detection study*

### Value of the study results and next steps



- Financial Snapshot / Cap Table
- Spin-Out / Out-License Programs
- Development Programs Overview
- Milestones Recap

# Financial Snapshot / Cap Table

## Financial Highlights as of September 30, 2025

Cash and Cash Equivalents \$1.3 million\*

No debt

\*Does not include **\$6.5 million** milestone payment related to our Boehringer Ingelheim collaboration in October 2025 and the net proceeds from our underwritten public offering of **\$16.9 million** in net proceeds which closed on November 12, 2025.

## Summary Capitalization as of December 31, 2025

### Common Shares and Equivalent

Common Stock	1.7 million shares
Warrants (includes PF warrants of ~2.1M)	8.5 million shares
Options and RSUs	0.1 million shares
Fully Diluted Shares	10.3 million shares
Total Shares Authorized	300.0 million shares

# Spin-Out / Out-License Programs

Product/Indication	R&D	Phase 1	Phase 2	Phase 3	NDA	Status/Next Steps
<b>Ocular</b> <b>PL9643 MCR Agonist</b> Dry eye disease (DED)						Phase 3 MELODY-1 completed - positive data Phase 3 Melody-2 & -3 potential initiation 2026  Sublicense Agreement with Altanispac Labs <b>January 2026</b>
<b>Proprietary MCR Agonists</b> Retinal Diseases						Research Collaboration / License Agreement with Boehringer Ingelheim <b>August 2025</b>
<b>Gastroenterology</b> <b>PL8177 Oral MC1R Agonist</b> Ulcerative colitis (UC)						Phase 2 Proof-of-Concept <b>Positive topline data reported 1Q25</b> Discussions Ongoing
<b>Renal</b> <b>MCR Agonist</b> Diabetic nephropathy						Phase 2 Open Label Trial <b>Positive topline data reported 4Q24</b> Discussions Ongoing

# Proprietary MCR Agonists for Treating Retinal Diseases

*Research Collaboration / License Agreement with Boehringer Ingelheim August 2025*

Boehringer Ingelheim and Palatin to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases.


- Collaboration strengthens Boehringer's pipeline in Eye Health.
- Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an unmet need.
- Melanocortin receptor agonists offer a promising, differentiated mechanism that targets key drivers of retinal diseases, including DR.

- Upfront payment of €2.0 million (\$2.3 million USD).
- Up to €18.0 million (\$20.9 million USD) in near-term research milestone payments.
- Up to €260 million (\$301.6 million USD) in success-based development, regulatory, and commercial milestone payments.
- Tiered royalties on net commercial sales of Products.



- DR, including diabetic macular edema (DME), **affects one in three people with diabetes** and is the **leading cause of blindness in working-age people**.
- Studies suggest that **patients with DME face 30-50% higher healthcare costs than those with diabetes alone**, underscoring the need for new approaches that mitigate the necessity of long-term, intensive care that often requires frequent monitoring and specialized procedures.

# Development Programs Overview

Pipeline Development Programs	Preclinical	Phase 1	Phase 2	Phase 3	NDA	Status/Next Steps
<b>PL7737 Oral Small Molecule MC4R Agonist</b> Multiple obesity indications with focus on hypothalamic obesity						IND enabling – CMC activities ongoing <b>IND filing 1H26</b> <b>Phase 1 SAD/MAD start 1H26 / data 2H26</b>
<b>Novel Once-Weekly Peptide MC4R Agonist</b> Multiple obesity indications with focus on hypothalamic obesity						IND enabling – CMC activities ongoing <b>IND filing mid-2026</b> <b>Phase 1 SAD/MAD start mid-2026 / data 2H26</b>
<b>Obesity</b> <b>Bremelanotide</b> Obesity - GLP-1 adjunct therapy Proof-of-concept study only						Phase 2 MC4R agonist + GLP-1 in obese patients initiated <b>Positive topline data reported 1Q25</b>
<b>Spin-Out / Out-License Product Candidates - Seeking Development &amp; Commercial Partnerships</b>						
<b>Ocular</b> <b>PL9643 MCR Agonist</b> Dry eye disease (DED)						Phase 3 MELODY-1 completed, positive data Phase 3 Melody-2 & -3 potential initiation 2026 Sublicense Agreement with Altanispac Labs – <b>January 2026</b>
<b>Proprietary MCR Agonists</b> Retinal diseases						Research Collaboration / License Agreement with Boehringer Ingelheim August 2025
<b>Gastroenterology</b> <b>PL8177 Oral MC1R Agonist</b> Ulcerative colitis (UC)						Phase 2 Proof-of-Concept <b>Positive topline data reported 1Q25</b> Discussions ongoing
<b>Renal</b> <b>MCR Agonist</b> Diabetic nephropathy						Phase 2 Open Label Trial <b>Positive topline data reported 4Q24</b> Discussions ongoing

# Milestones Recap

Melanocortin System Development Programs	Date
<b>Obesity - MC4R Agonists – Weight Loss (Maintenance)</b>	
Phase 2 BMT-801 Clinical Study Bremelanotide + GLP-1 (proof-of-concept study only) – Positive Topline Data Reported PL7737 MC4R Oral Small Molecule Agonist – IND Filing / SAD/MAD Data (Phase 1 to include HO patients) Novel MC4R Selective Long-Lasting Agonist – IND Filing / SAD/MAD Data (Phase 1 to include HO patients)	Completed 1H26 / 2H26 Mid-2026 / 2H26
<b>Spin-Out / Out-License Product Candidates: Seeking Development &amp; Commercial Partnerships</b>	
<b>PL9643 – Dry Eye Disease (DED)</b>	
Phase 3 Melody-1 Clinical Trial - Positive Results Reported Phase 3 Melody-2 and -3 Pivotal Clinical Trials Potential Initiation 2026	<b>Sublicense Agreement:</b> Altanispac Labs January 2026
<b>Proprietary MCR Agonists – Retinal Diseases (Preclinical Assets)</b>	
Research Collaboration / License Agreement with Boehringer Ingelheim	 Boehringer Ingelheim
<b>PL8177 Oral – Ulcerative Colitis</b>	Executed August 2025
Phase 2 Proof-of-Concept – Positive Topline Data Reported	Discussions Ongoing
<b>MC4R Agonist – Diabetic Nephropathy</b>	
Phase 2 Open Label Trial – Positive Topline Data Reported	Discussions Ongoing



Thank You.